AbbVie Stock Upgraded: What You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it under the microscope...
2017 has been a good year for owners of AbbVie (NYSE: ABBV) stock. Shares of the big pharma (market cap: $141.6 billion) are up more than 40% over the past year -- and up more than twice as much as the rest of the S&P 500. But now here's the best news of all: According to the analysts at Boston-based investment banker Leerink Partners, AbbVie stock is poised to keep on outperforming the S&P 500 for some time to come.
Here are three things you should know about that.
Source: Fool.com
Amgen Inc. Stock
€307.80
-0.210%
The stock is an absolute favorite of our community with 25 Buy predictions and no Sell predictions.
On the other hand, the target price of 304 € is below the current price of 307.8 € for Amgen Inc., so the potential is actually -1.23%.
